Abstracts

TDF/EVG Nanoparticle Formulation: Plasma Pharmacokinetics in Humanized Mice

One of the highest priorities of HIV research is to have access to long-acting pharmaceutical formulations for HIV treatment and prevention. Our research aims at fabrication of combination antiretroviral (cARV) drugs loaded nano-system for PReP.  Presently we report on the pharmacokinetics of tenofovir disoproxil fumurate (TDF) and elvitegravir (EVG) loaded nanoparticles (TDF+EVG NP) in humanized mice (huNSG). Formulation of cARV…

Antiretroviral Drug Use in a Cross-sectional Population Survey in Africa: HPTN 043

HIV Prevention Trials Network 043 (NIMH Project Accept) was a community-randomized trial in Africa and Thailand that assessed the impact of behavioral interventions on HIV incidence. Interventions were delivered over 3 years. HIV incidence was then assessed in a cross-sectional survey of >50,000 randomly-sampled adults (survey period: 2009-2011). At the African sites (34 communities at…

A Single Monotherapy Dose of MK-8591, a Novel NRTI, Suppresses HIV for 10 Days

MK-8591 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in early clinical development. MK-8591-triphosphate (TP), the active phosphorylated anabolite of MK-8591, exhibited protracted intracellular persistence in human and monkey peripheral blood mononuclear cells (PMBCs) in vitro. In preclinical experiments, MK-8591 administered once-weekly in an SIV rhesus macaque model demonstrated potent antiviral efficacy. Clinically, MK-8591-TP exhibited…

HIV Pretreatment Drug Resistance in Mexico: A Nationally Representative WHO Survey

To ensure sustainability of antiretroviral treatment (ART) programmes after ART scale up, the WHO has proposed a global standardized HIV drug resistance (DR) monitoring and surveillance strategy, including the assessment of pre-treatment HIVDR (PDR). We present the first nationally representative WHO HIV PDR survey performed in Mexico from February to July 2015. Twenty-five clinics were…

Large Cluster Clinical Isolates Show Facilitated Escape From Integrase Inhibitors

Background: Integrase inhibitors (INIs), including raltegravir (RGV), elvitegravir (EVG)  and dolutegravir (DTG) are a drug class of choice in first-line therapy. Emergent resistance to EVG and RGV include N155H and G140A/G148RHQ pathways, conferring RGV/EVG cross-resistance, and Y143RHC (RGV) and T66I/E92Q/G (EVG) pathways. To date, DTG shows a higher barrier to resistance with no reported mutations…

An Informatics Approach to Predicting Rates of Transmitted HIV-1 Drug Resistance

National transmitted HIV-1 drug resistance (TDR) rates are typically monitored through HIV surveillance data and this represents the gold-standard for determining TDR rates in various populations. However, it often requires several years to prepare data for presentation and publication resulting in long lag times between data accumulation and result dissemination. Here we present a computational…

Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART

Thymidine analogue mutations (TAMs; RT codons 41, 67, 70, 210, 215, 219) are a prevalent form of transmitted drug resistance (TDR) in Europe and North America, commonly occurring as singleton revertants of T215Y/F (e.g., T215E), and thought to often represent onward transmission from ART-naive subjects. Although PI/r-based therapy is recommended for patients with transmitted TAMs, it…

Cellular HIV-1 RNA/DNA As Biomarkers of Inducible Virion Production

Simple biomarkers of the inducible HIV-1 reservoir have not been identified. We investigated whether the frequency of infected cells in blood and their transcriptional activity is related to the inducible HIV-1 reservoir from resting CD4+ T cells in persons on virologically-suppressive antiretroviral therapy (ART). Total blood mononuclear cells (PBMC) were isolated from leukapheresis product obtained…